Human kallikrein related peptidases 6 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone

Cancer Biomarkers

Volumn 5, Issue 6, 2009, Pages 279-287

  White, Nicole M A ^a   Mathews, Maria ^a   Yousef, George M ^b   Prizada, Amrah ^a   Fontaine, Daniel ^a   Ghatage, Prafull ^c   Popadiuk, Catherine ^d   Dawson, Lesa ^d   Doré, Jules J E ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Health Sciences Centre St John's   (Canada)

Author keywords

Biomarkers; CA125; Human kallikrein related peptidase 13 (KLK13); Human kallikrein related peptidase 6 (KLK6); Mucin 16; Negative predictive value; Ovarian cancer; Positive predictive value; Sensitivity; Specificity

Indexed keywords

CA 125 ANTIGEN; KALLIKREIN 13; KALLIKREIN 6; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 76749143773     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0113     Document Type: Article

References (43)

1. A. Anisowicz, G. Sotiropoulou, G. Stenman, S.C. Mok and R. Sager, A novel protease homolog differentially expressed in breast and ovarian cancer, Mol Med 2 (1996), 624-636.
2. D. Badgwell and R.C. Bast, Jr., Early detection of ovarian cancer, Dis Markers 23 (2007), 397-410.
3. R.C. Bast, Jr., M. Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin and R.C. Knapp, Reactivity of a monoclonal antibody with human ovarian carcinoma, J Clin Invest 68 (1981), 1331-1337.
4. R.C. Bast, Jr., B. Hennessy and G.B. Mills, The biology of ovarian cancer: New opportunities for translation, Nat Rev Cancer, 9 (2009), 415-428.
5. M.J. Bernett, S.I. Blaber, I.A. Scarisbrick, P. Dhanarajan, S.M. Thompson and M. Blaber, The crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system, J Biol Chem 277 (2002), 24562-24570.
6. C.A. Borgono and E.P. Diamandis, The emerging roles of human tissue kallikreins in cancer, Nat Rev Cancer 4 (2004), 876-890.
7. Canadian Cancer Society's Steering Committee, Canadian Cancer Statistics 2009, Canadian Cancer Society, Toronto, 2009, 14-15.
8. M. Christie and M.K. Oehler, Molecular pathology of epithelial ovarian cancer, J Br Menopause Soc 12 (2006), 57-63.
9. M.R. Darling, L. Jackson-Boeters, T.D. Daley and E.P. Diamandis, Human kallikrein 6 expression in salivary gland tumors, J Histochem Cytochem 54 (2006), 337-342. (Pubitemid 43291278)
10. E.P. Diamandis, G.M. Yousef, A.R. Soosaipillai, L. Grass, A. Porter, S. Little et al., Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications, Clin Biochem 33 (2000), 369-375.
11. M.M. Fields and E. Chevlen, Screening for disease: making evidence-based choices, Clin J Oncol Nurs 10 (2006), 73-76.
12. M.C. Ghosh, L. Grass, A. Soosaipillai, G. Sotiropoulou and E.P. Diamandis, Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells, Tumour Biol 25 (2004), 193-199.
13. B.A. Goff, L. Mandel, H.G. Muntz and C.H. Melancon, Ovarian Cancer Diagnosis, Cancer 89 (2000), 2068-2075.
14. B.R. Hoffman, D. Katsaros, A. Scorilas, P. Diamandis, S. Fracchioli, I.A. Rigault de la Longrais et al., Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker, Br J Cancer 87 (2002), 763-771.
15. C.H. Holschneider and J.S. Berek, Ovarian cancer: epidemiology, biology, and prognostic factors, Semin Surg Oncol 19 (2000), 3-10.
16. J. Jacobs and R.C. Bast,The CA125 tumor associated antigen: a reviewof the literature, Human Reproduction 4 (1989), 1-12.
17. C. Kapadia, A. Chang, G. Sotiropoulou, G.M. Yousef, L. Grass, A. Soosaipillai et al., Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay, Clin Chem 49 (2003), 77-86.
18. C. Le Page, V. Ouellet, J. Madore, T.J. Hudson, P.N. Tonin, D.M. Provencher et al., From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serumbased markers in epithelial ovarian cancer, Int J Cancer 118 (2006), 1750-1758.
19. S.P. Little, E.P. Dixon, F. Norris,W. Buckley, G.W. Becker, M. Johnson et al., Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain, J Biol Chem 272 (1997), 25135-25142.
20. K.O. Lloyd, B.W. Yin and V. Kudryashov, Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule, Int J Cancer 71 (1997), 842-850.
21. L.Y. Luo, A. Soosaipillai, L. Grass and E.P. Diamandis, Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients, Tumour Biol 27 (2006), 227-234.
22. C. Marth, J. Kisic, J. Kaern, C. Trope and O. Fodstad, Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis, Cancer 94 (2002), 707-712.
23. M. Nakae, I. Iwamoto, T. Fujino, Y. Maehata, S. Togami, M. Yoshinaga et al., Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer, J Obstet Gynaecol Res 32 (2006), 309-314.
24. X. Ni, W. Zhang, K.C. Huang, Y. Wang, S.K. Ng, S.C. Mok et al., Characterisation of human kallikrein 6/protease M expression in ovarian cancer, Br J Cancer 91 (2004), 725-731.
25. H. Okamura and H. Katabuchi, Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis, Int Rev Cytol 242 (2005), 1-54.
26. W.C. Phillips, J.A. Scott and G. Blasczcynski, Statistics for diagnostic procedures. I. How sensitive is sensitivity; how specific is specificity?, AJR Am J Roentgenol 140 (1983), 1265-1270.
27. D.M. Robertson, E. Pruysers, H.G. Burger, T. Jobling, J. Mc- Neilage and D. Healy, Inhibins and ovarian cancer, Mol Cell Endocrinol 225 (2004), 65-71.
28. D.G. Rosen, L. Wang, J.N. Atkinson, Y. Yu, K.H. Lu, E.P. Diamandis et al., Potential markers that complement expres sion of CA125 in epithelial ovarian cancer, Gynecol Oncol 99 (2005), 267-277.
29. F. Ruckert, M. Hennig, C.D. Petraki, D. Wehrum, M. Distler, A. Denz et al., Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma, Br J Cancer 99 (2008), 1484-1492.
30. A. Rump, Y. Morikawa, M. Tanaka, S. Minami, N. Umesaki, M. Takeuchi et al., Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion, J Biol Chem 279 (2004), 9190-9198.
31. J.C. Schink, Current initial therapy of stage III and IV ovarian cancer: challenges for managed care, Semin Oncol 26 (1999), 2-7.
32. A. Scorilas, C.A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt et al., Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker, J Clin Oncol 22 (2004), 678-685.
33. I. Shih, R. Salani, M. Fiegl, T.L. Wang, A. Soosaipillai, C. Marth et al., Ovarian cancer specific kallikrein profile in effusions, Gynecol Oncol 105 (2007), 501-507.
34. M. Suzuki, M. Ohwada, I. Aida, T. Tamada, T. Hanamura and M. Nagatomo, Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer, Obstet Gynecol 82 (1993), 946-950.
35. H. Tanimoto, L.J. Underwood, K. Shigemasa, T.H. Parmley and T.J. O'Brien, Increased expression of protease M in ovarian tumors, Tumour Biol 22 (2001), 11-18.
36. B. Tringler, W. Liu, L. Corral, K.C. Torkko, T. Enomoto, S. Davidson et al., B7-H4 overexpression in ovarian tumors, Gynecol Oncol 100 (2006), 44-52.
37. N. Urban, Specific keynote: ovarian cancer risk assessment and the potential for early detection, Gynecol Oncol 88 (2003), S75-S79.
38. Y. Xu, Z. Shen, D.W.Wiper, M. Wu, R.E. Morton, P. Elson et al., Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers, JAMA 280 (1998), 719-723.
39. K. Yamashiro, N. Tsuruoka, S. Kodama, M. Tsujimoto, Y. Yamamura, T. Tanaka et al., Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain, Biochim Biophys Acta 1350 (1997), 11-14.
40. B.W. Yin and K.O. Lloyd, Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16, J Biol Chem 276 (2001), 27371-27375.
41. G. Yousef and E.P. Diamandis, Human Kallikreins: Common Structural features, Sequence Analysis and Evolution, Current Genomics 4 (2003), 147-165.
42. G.M.Yousef, A. Chang and E.P. Diamandis, Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues, J Biol Chem 275 (2000), 11891-11898.
43. Y. Zheng, D. Katsaros, S.J. Shan, l.L. de, I, M. Porpiglia, A. Scorilas et al., A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy, Clin Cancer Res 13 (2007), 6984-6992.